Abstract 5577
Background
ABBV-181 is a humanized, recombinant, IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1), incorporating an Fc mutation to limit FcgR-mediated effector function. Here we present preliminary ABBV-181 monotherapy data.
Methods
Patients (pts) with previously treated advanced solid tumors received ABBV-181 to progression at 1, 3, or 10 mg/kg IV Q2W (3 + 3 dose finding phase). Following dose finding, multi-histology, non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC) cohorts were opened. Dose limiting toxicities (DLTs) were assessed on days 1-28 of dose finding focused on immune mediated (IM) events, hemolysis, and cytopenia. Response is assessed Q8W per response evaluation criteria in solid tumors (RECIST v.1.1) and immune RECIST.
Results
As of January 15, 2018, 53 pts were treated with ABBV-181: 25 in dose finding, 17, 6, and 5 in multi-histology, HNSCC and NSCLC cohorts, respectively. Median age was 61 (range 27-84) years, 41% male, most frequent diagnoses in dose finding and multi-histology: cholangio, ovarian, breast and cervical carcinoma. Median days on study were 43 (range 1-379), 42 (79%) pts had ≥ 1 adverse event (AE), 22 pts (42%) had grade ≥ 3 AEs and 8 (15%) pts had IM AEs. The most frequent AEs of any grade were: fatigue (18 pts), constipation and vomiting (9 pts each). No DLTs were reported. ABBV-181 was discontinued in 33 (62%) pts, 27 for progression and 1 each for AEs of diabetic ketoacidosis, progression and small intestinal obstruction. PD-L1 was expressed on 7/21 (33%) available pretreatment samples (Dako 28-8 assay with 1% threshold). By investigator assessment, 4/34 (12%) pts with post baseline assessment responded (all in dose finding, all partial responses). Sustained PD-1 saturation on circulating CD4 T cells was observed at all doses. ABBV-181 pharmacokinetics (PK) were approximately dose-proportional in dose finding.
Conclusions
ABBV-181 monotherapy demonstrates target engagement and encouraging efficacy without unexpected safety signals. PK and pharmacodynamic data from dose finding support flat doses of 250 mg Q2W, 375 mg Q3W or 500 mg Q4W for expansion. Enrollment in the expansion cohorts continues.
Clinical trial identification
NCT03000257.
Legal entity responsible for the study
AbbVie Inc.
Funding
AbbVie Inc.
Editorial Acknowledgement
Disclosure
P.A. Cassier: Honoraria: Novartis, Roche-Genentech, Blueprint Medicines, Amgen; Institution research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck, Sharp and Dohme. K. Peltola: Advisory fees: Orion Pharma, BMS, MSD, Pfizer, Ipsen and Roche; Stock holder: Faron Pharmaceuticals. A.I. Spira: Consultant and institutional research support: AbbVie. M.M.E. Tanner: Finnish advisory board: Roche, Novartis, Pfizer; Speakers bureau: Roche, Novartis, Pfizer, Amgen. D. Afar, S. Englert, A. Parikh, A. Reddy, G. Vosganian: Employee and may own stock: AbbVie. A.W. Tolcher: Consultant: AbbVie. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract